ImmunityBio licenses oral vaccine tech from IosBio

By The Science Advisory Board staff writers

ImmunityBio has signed an exclusive worldwide licensing agreement for IosBio's OraPro vaccine platform technology that is currently being investigated in trials of ImmunityBio's second-generation human adenovirus 5 (hAd5) COVID-19 vaccine candidate.

OraPro is a patented oral delivery vaccine platform which enables the oral administration of thermally stable viral vector vaccines. The vectors are engineered to withstand temperatures of up to 50° C, allowing them to pass through the stomach without losing efficacy and providing long-term product stability at ambient temperatures. Oral administration of vaccines stimulates mucosal-associated lymphoid tissue to generate mucosal, systemic, and T-cell immune responses.

The hAd5 COVID-19 vaccine candidate has shown promising results in preclinical studies and is working with the U.S. Food and Drug Administration to initiate a phase I prime/boost clinical trial. So far, 20 participants have already been dosed with both low and high doses of the vaccine in a phase I trial with no serious adverse events.

Under the agreement, IsoBio has granted ImmunityBio exclusive rights to utilize the platform for ImmunityBio's COVID-19 vaccine. IsoBio will be eligible to receive royalties on net worldwide sales of the approved oral vaccine.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?